LOCALLY ADVANCED UNRESECTABLE GASTROESOPHAGEAL JUNCTION (GEJ) ADENOCARCINOMA OR CANCER
Clinical trials for LOCALLY ADVANCED UNRESECTABLE GASTROESOPHAGEAL JUNCTION (GEJ) ADENOCARCINOMA OR CANCER explained in plain language.
Never miss a new study
Get alerted when new LOCALLY ADVANCED UNRESECTABLE GASTROESOPHAGEAL JUNCTION (GEJ) ADENOCARCINOMA OR CANCER trials appear
Sign up with your email to follow new studies for LOCALLY ADVANCED UNRESECTABLE GASTROESOPHAGEAL JUNCTION (GEJ) ADENOCARCINOMA OR CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Doctors track new stomach cancer Drug's Real-World side effects
Disease control Recruiting nowThis study is collecting information on the safety of VYLOY, an already approved drug, for people in South Korea with advanced stomach or gastroesophageal junction cancer that cannot be removed by surgery. About 377 patients receiving VYLOY as part of their standard care will be …
Matched conditions: LOCALLY ADVANCED UNRESECTABLE GASTROESOPHAGEAL JUNCTION (GEJ) ADENOCARCINOMA OR CANCER
Sponsor: Astellas Pharma Korea, Inc. • Aim: Disease control
Last updated Mar 30, 2026 14:29 UTC
-
New hope for advanced stomach cancer: phase 3 trial tests targeted combo therapy
Disease control Recruiting nowThis study is testing whether adding a new drug called zolbetuximab to standard immunotherapy and chemotherapy helps people with advanced stomach or gastroesophageal (GEJ) cancer live longer. It is for adults whose cancer has spread, cannot be removed by surgery, and has specific…
Matched conditions: LOCALLY ADVANCED UNRESECTABLE GASTROESOPHAGEAL JUNCTION (GEJ) ADENOCARCINOMA OR CANCER
Phase: PHASE3 • Sponsor: Astellas Pharma Global Development, Inc. • Aim: Disease control
Last updated Mar 23, 2026 15:15 UTC